Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.

Permalink
https://escholarship.org/uc/item/3v84r2cw

Journal
Cancer medicine, 6(1)

ISSN
2045-7634

Authors
Miller, Eric T
Chamie, Karim
Kwan, Lorna
et al.

Publication Date
2017

DOI
10.1002/cam4.981

Peer reviewed
**Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer**

Eric T. Miller¹, Karim Chamie¹, Lorna Kwan¹, Michael S. Lewis², Beatrice S. Knudsen³ & Isla P. Garraway¹,4,5

¹Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California
²Department of Pathology, Greater Los Angeles Veterans Affairs Health System, Los Angeles, California
³Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California
⁴Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California
⁵Division of Urology, Greater Los Angeles Veterans Affairs Healthcare Center, Los Angeles, California

**Keywords**
ADT, disease progression, HGPC, risk

**Abstract**

Men with high-grade prostate cancer (HGPC) are at greatest risk of disease progression. Clinical risk factors associated with castration-resistant prostate cancer (CRPC), metastases, and prostate cancer-specific mortality (PCSM) were identified in a contemporary HGPC cohort. Clinical data was collected from men diagnosed with Gleason sum (GS) ≥8 at the Greater Los Angeles Veterans Affairs (GLA-VA) Healthcare System between 2000 and 2013. Multivariable competing risks regression analyses assessed progression to CRPC, metastases, and PCSM within three treatment strata. The cumulative incidence of disease progression was calculated at 2, 5, and 10-year time points. Review of 2149 prostate cancer cases yielded 322 with HGPC. Median survival times for cancer-specific and overall mortality were significantly shorter in men treated with primary androgen deprivation therapy (ADT) (P = 0.0002 and P < 0.0001). Multivariable analyses revealed that clinical stage N1, GS 10, and treatment with primary ADT were significantly associated with increased risk of CRPC, metastases, and PCSM. Significant differences in these outcomes were not observed in men treated with radical prostatectomy (RP) when compared to those treated with radiation therapy combined with short-term ADT (XRT-ADT). Ten-year event rates of progression to CRPC, metastases, and PCSM, for men treated with primary ADT, were 45.5%, 25.4%, and 25.1%, respectively. In conclusion, GS 10 and lymph node involvement, as well as primary ADT treatment in men with HGPC was associated with increased risk of CRPC, metastases, and PCSM. Curative-intent treatment with RP or XRT-ADT is associated with reduced progression rates and death in men with HGPC.

**Introduction**

To predict the risk of disease recurrence following definitive treatment for localized prostate cancer (PC), risk stratification tools often integrate Gleason sum (GS), prostate specific antigen (PSA), and clinical tumor (cT) stage [1–3]. In the commonly used D’Amico risk classification, these variables enable newly diagnosed men to be assigned to low (GS <6, PSA<10 ng/mL, cT1c or cT2a), intermediate (GS 7, PSA 10-20 ng/mL, cT2b), or high (GS ≥8, PSA ≥20 ng/mL, ≥cT2c) risk groups following treatment [3]. In the current PSA screening era,
approximately 15% of men with newly diagnosed PC display high-risk disease [4, 5]. Since metastatic progression is often observed within 5 years of treatment, it is postulated that many who fail curative-intent therapy harbor micro-metastatic disease at diagnosis that is undetectable with standard-of-care imaging modalities [6]. In order to improve disease control in such ‘very’ high-risk cases, combinational approaches will be needed [7, 8].

Most risk stratification schemes place men at high risk of progression if high-grade PC (HGPC), designated by pathological Gleason sum $\geq 8$, is identified in diagnostic biopsy and/or prostatectomy specimens [1–3, 9]. However, HGPC is a heterogeneous disease, representing a wide range of pathological features and clinical outcomes [10, 11]. Intervention with curative-intent therapies, including radical prostatectomy (RP) or external beam radiation therapy combined with short-term androgen deprivation therapy (XRT-ADT), is associated with 10-year PC survival rates as high as 98%, despite biochemical recurrence (BCR) in approximately one-third of these men. Thus, sequential rises in PSA following treatment for PC, which defines BCR, are not always associated with metastatic progression or shorter survival [6, 9]. Notably, metastasis-free survival intervals of 10 years have been observed in men with BCR following RP, even in the absence of salvage therapies (XRT and/or ADT) [12, 13]. Recent results from the STAMPEDE clinical trial have demonstrated that the addition of docetaxel to standard treatments for high-risk, non metastatic PC is associated with a significantly improved failure-free survival [14]. If the results of this randomized-controlled trial are further validated, there may be a paradigm shift in the clinical management of high-risk patients. However, given that only a subset of men with BCR experience lethal progression, improved tools are needed to delineate men at highest risk of castration-resistant PC (CRPC), metastases, or death from PC. These tools will help to target men most likely to benefit from combinational treatment approaches and prevent unnecessary exposure to adverse effects associated with adjuvant and/or salvage therapies [4, 7, 14, 15].

In the current study, we examined a diverse cohort of men with localized HGPC who were diagnosed and treated within the Greater Los Angeles Veterans Affairs (GLA-VA) Healthcare System between 2000 and 2013. All cases are part of a biorepository that was designed to facilitate future molecular profiling of PC specimens. Disease progression outcomes were analyzed by three treatment strata: RP, XRT-ADT, and primary androgen deprivation therapy (ADT). Given the heterogeneous nature of HGPC, we hypothesized that clinical variables present at diagnosis, as well as treatment choice, a variable that is not commonly assessed in PC outcomes studies but closely linked with metastases and prostate cancer-specific mortality (PCSM), are associated with time to CRPC. The overall goal of this study was to identify variables associated with meaningful clinical progression (CRPC, metastases, death from PC) in men diagnosed with HGPC.

**Methods**

**Study population**

After obtaining institutional review board approval at the GLA-VA, the Cancer Registry, housed at the GLA-VA, was queried to identify men diagnosed with PC between 2000 and 2013 ($n = 2,149$). Electronic medical record review enabled abstraction of demographic and clinical variables and generation of a GLA-VA PC database. We excluded cases with distant metastatic disease at diagnosis (clinical stage M1, $n = 114$), cases for which metastatic burden was not assessed or demonstrated equivocal results (clinical stage Mx, $n = 234$), and those who received active surveillance, watchful waiting, declined treatment, or left the VA healthcare system ($n = 301$). To derive the cohort with HGPC used for this study, cases with diagnostic pathological reports documenting a GS $\leq 7$ ($n = 1,178$) were excluded. Only cases with Gleason sum $\geq 8$ (denoted on the pathological reports from prostate biopsies, RP, simple prostatectomy, or transurethral resection of prostate specimens) were included for the final study population, which resulted in 322 men (Fig. 1).

**Variables**

**Race/ethnicity**

Race and ethnicity were abstracted from the VA Computerized Patient Record System (CPRS), where race was recorded as White, Black or African American, Asian, Native Hawaiian or other Pacific Islander, Native American, Unknown, or Unanswered. Ethnicity was recorded as Hispanic or Latino, not Hispanic or Latino, unknown, or un answered. For the HGPC cohort, race was categorized as White, Black, and Other.

**Clinical Stage and Tumor Characteristics**

The clinical tumor (cT) stage was dichotomized into T1/T2 and T3/T4. PSA at the time of diagnosis was dichotomized into $\leq 20$ ng/mL and $>20$ ng/mL. Gleason sum was categorized as 8, 9, or 10. The centralized pathological review was performed on a subset of cases (approximately 20%) by a genitourinary pathologist who was blinded to clinical outcomes in order to confirm appropriate and consistent designation of pathological grade. To assign the clinical lymph node (N) stage, diagnostic computed tomography (CT) or magnetic
resonance imaging (MRI) scans were reviewed. If lymph node metastases were not identified, the case was designated as N0. If pelvic lymph node metastases were present, the case was designated as N1. If imaging studies were absent or inconclusive, the cases were designated as Nx. Pathological N-stage, obtained from patients who underwent RP with concurrent pelvic lymph node dissection, was not considered in this analysis.

**Type of primary treatment**

The primary definitive treatment following a diagnosis of PC was abstracted from CPRS. Men were categorized by primary treatment received, including RP, XRT-ADT, and primary continuous ADT. Men treated with XRT-ADT received the standard of care external beam radiation and short-term ADT at the discretion of the treating physicians.

**Disease progression**

The development of CRPC and metastases were documented as yes/no events. The development of CRPC was defined as (1) two sequential rises in PSA, (2) metastatic progression while on ADT, or (3) initiation of CRPC treatment, whichever came first. Metastatic disease was confirmed by sequential imaging modalities (i.e., Technetium-99 bone scan, CT or MRI scans). Length of follow-up was calculated for each outcome from date of diagnosis to date of disease progression, or to date of most recent clinical contact for those without progression.

**Mortality**

Each chart was independently reviewed by the primary and senior author to assess specific cause of death and coded as follows: alive, death from PC, or death from other cause. Death from PC was noted if the patient was documented to have metastatic disease and died in hospital of related complications or died in hospice care. Survival time was computed from date of diagnosis to the date of death, or from date of diagnosis to the date of most recent clinical contact for censored cases.

**Statistical analysis**

The HGPC cohort was separated into three subcohorts based upon treatment received: RP, \( n = 106 \) (33%); XRT-ADT, \( n = 138 \) (43%); primary ADT, \( n = 78 \) (24%). Bivariable analysis compared patient characteristics across the subcohorts, using chi-square and Fisher’s exact tests for categorical variables and ANOVA for continuous variables. Kaplan–Meir survival analysis was performed for PCSM and all-cause mortality stratified by treatment received. Multivariable competing risks regression models were constructed to identify variables associated with the development of CRPC, metastases, and PCSM. Death from other causes was coded as the competing risk for disease progression analyses and non-PC mortality was coded as the competing risk in PCSM analysis. Variables evaluated in the models included age at diagnosis, race (White as referent), dichotomized PSA (≤20 ng/mL as referent), Gleason sum (eight as referent), dichotomized T-Stage (T1/T2 as referent), clinical N-Stage (N0 as referent), and primary treatment received (XRT-ADT as referent). Cumulative incidence curves for each subcohort were generated from the resulting models. Predicted 2, 5, and 10-year progression event rates were calculated for CRPC, metastases, and PCSM for each treatment strata. All tests were two-sided and a statistical \( P < 0.05 \) was used to denote significance. Analyses were performed, using Stata.
Results

Patient characteristics

Clinical and pathological characteristics from the study subjects stratified by the three treatments received are shown in Table 1. The median age of the HGPC cohort was 66.2 years (range 38.4–90.4 years). Men treated with primary ADT were more likely to be older, Black, and have clinical N1 stage compared to men treated with XRT-ADT and RP \((P < 0.0001, P = 0.0393\) and \(P = 0.0047\), respectively). There were no statistical differences in Gleason sum, time to CRPC, time to metastases, time to death from PC, or time to death from any cause among the treatment groups. Overall, 15.3\% of men in the HGPC cohort developed CRPC, 14.2\% developed metastases, and 9.7\% experienced PCSM.

Disease progression and survival analysis

Kaplan–Meier survival analysis for PCSM stratified by treatment received revealed that median survival was never reached in the RP and XRT-ADT treatment groups by the end of follow-up period (i.e. \(>50\%\) of the patients were still alive) (Fig. 2). However, the median time to PCSM was 165 months for men who received primary ADT, which was significantly shorter than for men treated with RP and XRT-ADT \((P = 0.0002)\). The median time to all-cause mortality was 116 months for men who received XRT-ADT and 71 months for those who received primary ADT \((P < 0.0001)\). Approximately 57\% of the RP subcohort did not die during the course of the follow-up period.

Results from the multivariable competing risks regression analyses are shown in Table 2. There was an increased risk for all progression events in men with N1 and GS 10 disease. Cumulative incidence curves from the competing risks regression analyses and predicted 2, 5, and 10-year disease event progression rates for CRPC, metastases and PCSM stratified by treatment received are shown in Figure 3 and Table 3, respectively.

Discussion

Men with newly diagnosed localized HGPC may select management of their disease with curative intent treatments such as RP, XRT-ADT, or opt for observation, surveillance, and/or palliation. It is well documented that men with HGPC at the time of biopsy or RP have a high risk of BCR and clinical progression [18]. However, it is important to consider that not all of these patients will, in fact, recur; and for those with BCR, not all will experience metastatic or lethal progression [10]. New data from the STAMPEDE clinical trial have demonstrated a significant reduction in disease recurrence in men with high-risk, localized PC treated with upfront docetaxel in combination with standard of care therapy [14]. Since high-risk disease (which includes men with HGPC) accounts for approximately 15\% of new localized PC diagnoses, it is important to attempt sub-stratification of these men in order to identify those most likely to benefit from upfront combinatorial therapy and reduce morbidity associated with adverse effects from chemotherapy or other adjuvant treatments [19–21].

In accordance with previous studies, we found few clinical or pathological variables associated with progression to CRPC, metastases or death from PC in the analysis of this HGPC cohort [9]. However, multivariable analysis controlling for treatment received revealed a significant association with GS 10 tumors and poorer outcomes. The prognostic value of Gleason score remains a principal reason why it is integrated into risk stratification [2, 3, 7, 22, 23]. While studies consistently demonstrate that GS 8–10 tumors are associated with worse prognosis, there remains a wide distribution of outcomes among men with HGPC [11, 24]. This was observed in our analysis, where GS 10 was the only pathological feature associated with disease progression. This finding demonstrates that the highest Gleason score along the continuum correlates with a higher risk of progression. However, since men who progressed also displayed GS 8 and GS 9 tumors, aspects of tumor biology that are not captured with the Gleason score alone may contribute to outcome as well.

Previous analysis of VA men with Gleason sum $\geq 8$ disease identified in the SEARCH database that were treated with RP revealed that adverse pathological features found in the surgical specimen, including seminal vesicle invasion, extracapsular extension, or positive surgical margins, were associated with increased risk of early BCR [10]. Although these features are useful for identifying RP patients that may benefit from combinatorial therapies, they cannot be used for men who chose nonsurgical PC management. Additional factors that can be determined at diagnosis are needed to predict prognosis and assist with management decisions in nonsurgical HGPC cases, especially if new clinical trial evidence will encourage a more aggressive approach for those with newly diagnosed HGPC.

Our results demonstrated that men treated with primary ADT had worse outcomes, including a higher rate of CRPC, metastasis, and death from PC. These findings suggest that RP or XRT-ADT may be superior treatment choices for men with HGPC. The role of primary ADT
Table 1. Patient characteristics stratified by primary treatment received.

| Initial Stage and Treatment | Total (N = 322) | RP (N = 106) | XRT-ADT (N = 138) | ADT (N = 78) | P-value |
|-----------------------------|-----------------|--------------|--------------------|--------------|---------|
| Age                         |                 |              |                    |              | <0.0001 |
| Mean (SD)                   | 67.3 (8.4)      | 62.8 (6.7)   | 68.3 (7.4)         | 71.7 (9.4)   |         |
| Median                      | 66.2            | 63.7         | 67.6               | 72.3         |         |
| Range                       | 38.0–90.4       | 38.0–78.2    | 49.0–84.3          | 51.3–90.4    |         |
| Race                        |                 |              |                    |              | 0.0393  |
| White                       | 151 (46.9%)     | 55 (51.9%)   | 70 (50.7%)         | 26 (33.3%)   |         |
| Black                       | 133 (41.3%)     | 40 (37.7%)   | 56 (40.6%)         | 37 (47.4%)   |         |
| Other                       | 38 (11.8%)      | 11 (10.4%)   | 12 (8.7%)          | 15 (19.2%)   |         |
| Clinical T-Stage            |                 |              |                    |              | 0.0304  |
| T1 or T2                    | 273 (86.4%)     | 95 (91.4%)   | 118 (87.4%)        | 60 (77.9%)   |         |
| T3 or T4                    | 43 (13.6%)      | 9 (8.7%)     | 17 (12.6%)         | 17 (22.1%)   |         |
| Clinical N-Stage            |                 |              |                    |              | 0.0047  |
| N0                          | 213 (66.2%)     | 74 (69.8%)   | 101 (73.2%)        | 38 (48.7%)   |         |
| N1                          | 54 (16.8%)      | 16 (15.1%)   | 20 (14.5%)         | 18 (23.1%)   |         |
| Nx                          | 55 (17.1%)      | 16 (15.1%)   | 17 (12.3%)         | 22 (28.2%)   |         |
| Gleason sum                 |                 |              |                    |              | 0.3962  |
| 8                           | 195 (60.6%)     | 66 (62.3%)   | 83 (60.1%)         | 46 (59.0%)   |         |
| 9                           | 120 (37.3%)     | 40 (37.7%)   | 50 (36.2%)         | 30 (38.5%)   |         |
| 10                          | 7 (2.2%)        | 0 (0%)       | 5 (3.6%)           | 2 (2.6%)     |         |
| PSA Category (ng/mL)        |                 |              |                    |              | <0.0001 |
| ≤20                         | 244 (76.5%)     | 98 (95.2%)   | 107 (77.5%)        | 39 (50.0%)   |         |
| >20                         | 75 (23.5%)      | 5 (4.9%)     | 31 (22.5%)         | 39 (50.0%)   |         |
| PSA at Diagnosis (ng/mL)    |                 |              |                    |              | <0.0001 |
| Median                      | 10.0            | 6.7          | 9.8                | 19.9         |         |
| Range                       | 0.1–1329.0      | 1.7–53.3     | 0.1–172.4          | 3.8–1328.0   |         |
| Development of CRPC         |                 |              |                    |              | <0.0001 |
| No                          | 261 (84.7%)     | 95 (93.1%)   | 119 (88.2%)        | 47 (66.2%)   |         |
| Yes                         | 47 (15.3%)      | 7 (6.9%)     | 16 (11.9%)         | 24 (33.8%)   |         |
| Time to CRPC (mo)           |                 |              |                    |              | 0.8112  |
| Mean (SD)                   | 38.3 (30.6)     | 46.0 (40.1)  | 37.5 (25.3)        | 37.0 (32.4)  |         |
| Median                      | 32.0            | 32.3         | 30.7               | 32.7         |         |
| Range                       | 3.7–128.2       | 13.3–119.1   | 7.2–90.7           | 3.7–128.2    |         |
| Development of Metastases   |                 |              |                    |              | 0.0052  |
| No                          | 273 (85.8%)     | 92 (87.6%)   | 125 (90.6%)        | 56 (74.7%)   |         |
| Yes                         | 45 (14.2%)      | 13 (12.4%)   | 13 (9.4%)          | 19 (25.3%)   |         |
| Time to Metastases (mo)     |                 |              |                    |              | 0.9600  |
| Mean (SD)                   | 52.0 (42.8)     | 54.3 (52.6)  | 49.1 (33.6)        | 52.4 (43.0)  |         |
| Median                      | 39.6            | 40.4         | 37.3               | 39.9         |         |
| Range                       | 2.3–174.6       | 4.6–174.6    | 16.4–106.5         | 2.3–160.5    |         |
| Vital Status                |                 |              |                    |              | <0.0001 |
| Alive                       | 214 (66.9%)     | 93 (87.7%)   | 89 (64.5%)         | 32 (42.1%)   |         |
| Death from PC               | 31 (9.7%)       | 5 (1.6%)     | 10 (7.3%)          | 16 (21.1%)   |         |
| Death from any cause        | 75 (23.4%)      | 8 (7.6%)     | 39 (28.3%)         | 28 (36.8%)   |         |
| Time to Death from PC (mo)  |                 |              |                    |              | 0.7274  |
| Mean (SD)                   | 63.7 (40.4)     | 77.1 (46.8)  | 62.3 (34.1)        | 60.3 (43.8)  |         |
| Median                      | 56.2            | 48.7         | 59.9               | 53.4         |         |
| Range                       | 12.1–165.2      | 39.2–143.5   | 19.0–122.8         | 12.1–165.1   |         |
| Time to Death from any cause (mo) |         |              |                    |              | 0.1291  |
| Mean (SD)                   | 59.9 (38.6)     | 65.8 (36.5)  | 66.4 (38.0)        | 50.9 (38.9)  |         |
| Median                      | 51.6            | 54.1         | 60.4               | 43.1         |         |
| Range                       | 2.4–170.0       | 12.7–143.5   | 9.3–170.0          | 2.4–165.2    |         |
| Length of Follow-up (mo)    |                 |              |                    |              | 0.0103  |
| Mean (SD)                   | 67.1 (39.2)     | 63.6 (35.7)  | 74.4 (39.7)        | 58.8 (41.0)  |         |
| Median                      | 58.2            | 52.4         | 64.6               | 51.6         |         |
| Range                       | 0.0–185.0       | 1.3–174.6    | 0.0–185.0          | 2.4–173.4    |         |

ADT, primary androgen deprivation therapy; RP, radical prostatectomy; XRT-ADT, radiation therapy combined with short-term ADT; CRPC, castration-resistant prostate cancer; PC, prostate cancer; mo, months; PSA, prostate specific antigen
in nonmetastatic PC is controversial without clear evidence of offering a survival benefit, however, some men are offered and accept this choice of treatment for different reasons, such as suspicion of micrometastatic disease due to high PSA at diagnosis, or patient preference for a noninvasive treatment option [16, 17]. ADT is often associated with multiple adverse effects, including increased risk of cardiovascular disease, venous
thromboembolism, peripheral arterial disease, and negative quality of life factors [25–27]. Therefore, it is important to consider possible adverse effects of ADT and the increased rate of lethal progression when managing localized HGPC.

Several studies have evaluated the benefit of curative-intent therapy in men with high-risk PC. In randomized trials based in Scandinavia, the UK, and North America, there were significant improvements in disease-free and overall survival in men treated with combination radiation therapy and ADT compared with ADT alone [28, 29]. Additionally, several large retrospective studies demonstrated improved survival rates in high-risk men treated with RP, with 10-year cancer-specific survival ranging from 82% to 92% [19, 30, 31]. The results of our retrospective analysis are consistent with these reports, and our survival outcomes among men treated with curative-intent therapy were comparable.

A noteworthy finding among this diverse cohort of men was the lack of association between race and disease progression. Our study revealed equal distribution of HGPC among Black and White men and race was not a factor that contributed to risk of CRPC, metastasis, or PCSM [32–34]. These results are consistent with a prior study of men with nonmetastatic PC diagnosed and treated within the GLA-VA Healthcare System, which also found no racial differences associated with HGPC and outcome [35]. However, closer evaluation of the distribution of GS among all men diagnosed and treated with PC at GLA-VA between 2000 and 2013 is needed to make firm conclusions that similar proportions of White and Black men display HGPC. Our analysis did, in fact, reveal differences in treatment selection associated with race. Significantly fewer Black men in the HGPC cohort were treated with RP, opting for XRT-ADT or primary ADT. Identifying reasons for this observation are beyond the scope of this study, however previous analyses indicate that they are likely multifactorial [36, 37]. Dedicated studies focused on close examination of PC racial disparities within the VA are needed in order to better understand a potential impact on tumor biology and/or clinical outcome.

Our retrospective outcomes analysis has some specific limitations. The HGPC cohort includes a wide range of patients diagnosed and treated by many different healthcare providers within the GLA-VA, so there may be inconsistencies in designation of clinical T-stage based upon clinical examination. Although all patients in our study underwent metastatic evaluation, including...
documented bone, CT and/or MRI scans at the time of diagnosis, there was no standardized protocol for monitoring patients following treatment. Follow-up PSA testing and metastatic imaging were performed at the discretion of the treating physician, so the precise timing of disease recurrence and/or progression may not be accurately reflected in the dates of PSA or imaging results. Other confounding factors that were not included in this study were comorbidities, performance status, and socioeconomic status. Finally, the fact that our cohort was composed entirely of Veterans may raise concern about the generalizability of our results to other populations of men with HGPC. However, the single institution also represents the strength of this study because it enables maximal length of follow-up, and the options for care and delivery are relatively consistent. By conducting competing risks analyses, we have accounted for alternative causes of death (other than PC), which strengthens the validity of our results. Thus, comparison across treatment sub-cohorts in this VA study is relevant and comparable with other VA and non-VA studies focused on outcomes of men with high risk PC.

In conclusion, clinical stage N1, GS 10, and treatment with primary ADT were associated with lethal PC progression in a contemporary cohort of men diagnosed and treated for HGPC in an equal access VA healthcare system. Men with HGPC who receive definitive therapy (RP or XRT-ADT) had significantly improved PC-specific and overall survival compared to men treated with primary ADT. These findings suggest that curative-intent treatments should be considered in men with newly diagnosed HGPC. However, a subset of men with HGPC will progress to CRPC, metastases, or death from PC despite receiving curative-intent treatment. This subset will benefit from improved risk stratification and potential combinatorial therapies. Given the limited contribution of clinical variables in predicting lethal progression in HGPC cases, future integration of molecular profiles generated from PC specimens linked to this dataset may help generate improved classifiers for men with newly diagnosed HGPC and designate men at highest risk of disease progression.

Table 3. Multivariable predicted disease progression event rates stratified by treatment received.

|                | CRPC 2-year | CRPC 5-year | CRPC 10-year | Metastases 2-year | Metastases 5-year | Metastases 10-year | PCSM 2-year | PCSM 5-year | PCSM 10-year |
|----------------|-------------|-------------|--------------|-------------------|-------------------|-------------------|-------------|-------------|--------------|
| RP             | 1.8%        | 4.8%        | 8.1%         | 3.5%              | 8.9%              | 17.5%             | 1.0%       | 3.1%       | 9.0%         |
| XRT-ADT        | 2.8%        | 7.5%        | 12.6%        | 1.5%              | 4.0%              | 8.1%              | 0.9%       | 2.8%       | 8.2%         |
| ADT            | 12.1%       | 29.7%       | 45.5%        | 5.2%              | 13.2%             | 25.4%             | 3.1%       | 9.1%       | 25.1%        |

ADT, primary androgen deprivation therapy; RP, radical prostatectomy; XRT-ADT, radiation therapy combined with short-term ADT; CRPC, castration-resistant prostate cancer; PCSM, prostate cancer specific mortality.

Conflicts of Interest
None.

References
1. Cooperberg, M. R., D. J. Pasta, E. P. Elkin, M. S. Litwin, D. M. Latini, J. Du Chane, et al. 2005. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 173:1938–1942.
2. Mohler, J. L., P. W. Kantoff, A. J. Armstrong, R. R. Bahnson, M. Cohen, A. V. D’Amico, et al. 2014. Prostate cancer, version 2.2014. J. Natl. Compr. Canc. Netw. 12:686–718.
3. D’Amico, A. V., R. Whittington, S. B. Malkowicz, D. Schultz, K. Blank, G. A. Broderick, et al. 1998. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974.
4. Bastian, P. J., S. A. Boorjian, A. Bossi, A. Briganti, A. Heidenreich, S. J. Freedland, et al. 2012. High-risk prostate cancer: from definition to contemporary management. Eur Urol. 61:1096–1106.
5. Cooperberg, M. R., J. M. Broering, and P. R. Carroll. 2010. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 28:1117–1123.
6. Paller, C. J., and E. S. Antonarakis. 2013. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol. 11:14–23.
7. Chang, A. J., K. A. Autio, M. Roach 3rd, and H. I. Scher. 2014. High-risk prostate cancer: classification and therapy. Nat Rev Clin Oncol. 11:308–323.
8. Bastian, P. J., M. L. Gonzalgo, W. J. Aronson, M. K. Terris, C. J. Kane, C. L. Amling, et al. 2006. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer. 107:1265–1272.
9. Freedland, S. J., E. B. Humphreys, L. A. Mangold, M. Eisenberger, F. J. Dorey, P. C. Walsh, et al. 2005. Risk
of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 294:433–439.
10. Fischer, S., D. Lin, R. M. Simon, L. E. Howard, W. J. Aronson, M. K. Terris, et al. 2016. Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database. BJU Int. 118:250–257.
11. Gordetsky, J., and J. Epstein. 2016. Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol. 11:25.
12. Antonarakis, E. S., Z. Feng, B. J. Trock, E. B. Humphreys, M. A. Carducci, A. W. Partin, et al. 2012. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 109:32–39.
13. Antonarakis, E. S., Y. Chen, S. I. Elsamanoudi, S. A. Brassell, M. V. Da Rocha, M. A. Eisenberger, et al. 2011. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int. 108:378–385.
14. James, N. D., M. R. Sydes, N. W. Clarke, M. D. Mason, D. P. Dearnaley, M. R. Spears, et al. 2016. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 387:1163–1177.
15. Punnen, S., and M. R. Cooperberg. 2013. The epidemiology of high-risk prostate cancer. Current Opin Urol. 23:331–336.
16. Helgstrand, J. T., K. D. Berg, S. Lippert, K. Brasso, and M. A. Roder. 2016. Systematic review: does endocrine therapy prolong survival in patients with prostate cancer? Scand J Urol. 50:135–143.
17. Lu-Yao, G. L., P. C. Albertsen, D. F. Moore, W. Shih, Y. Lin, R. S. DiPaola, et al. 2014. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer. JAMA Intern Med. 174:1460–1467.
18. Soloway, M., and M. Roach 3rd. 2005. Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era. Cancer. 104:2310–2322.
19. Briganti, A., S. Joniau, P. Gontero, F. Abdollah, N. M. Passoni, B. Tombal, et al. 2012. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol. 61:584–592.
20. Bolton, D. M., A. Ta, M. Bagnato, D. Muller, N. L. Lawrencechuk, G. Severi, et al. 2014. Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer. World J Urol. 32:431–435.
21. Tanguay, J. S., C. Catlow, C. Smith, J. Barber, J. Staffurth, J. S. Kumar, et al. 2016. High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice. Clin Oncol (R Coll Radiol). 28:611.
22. Scher, H. I., and G. Heller. 2000. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology. 55:323–327.
23. Kattan, M. W., J. A. Eastham, A. M. Stapleton, T. M. Wheeler, and P. T. Scardino. 1998. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 90:766–771.
24. Wadosky, K. M., and S. Koochekpour. 2016. Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. Int J Biol Sci. 12:409–426.
25. Hu, J. C., S. B. Williams, A. J. O’Malley, M. R. Smith, P. L. Nguyen, and N. L. Keating. 2012. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 61:1119–1128.
26. Potosky, A. L., B. B. Reeve, L. X. Clegg, R. M. Hoffman, R. A. Stephenson, P. C. Albertsen, et al. 2002. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst. 94:430–437.
27. Saigal, C. S., J. L. Gore, T. L. Krupski, J. Hanley, M. Schonlau, and M. S. Litwin. 2007. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 110:1493–1500.
28. Widmark, A., O. Klepp, A. Solberg, J. E. Damber, A. Angelsen, P. Fransson, et al. 2009. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 373:301–308.
29. Warde, P., M. Mason, K. Ding, P. Kirkbride, M. Wadosky, R. Cowan, et al. 2011. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 378:2104–2111.
30. Eggener, S. E., P. T. Scardino, P. C. Walsh, M. Han, A. W. Partin, B. J. Trock, et al. 2011. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 185:869–875.
31. Boorjian, S. A., R. J. Karnes, R. Viterbo, L. J. Rangel, E. J. Bergstrahl, E. M. Horwitz, et al. 2011. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 117:2883–2891.
32. Albain, K. S., J. M. Unger, J. J. Crowley, C. A. Coltman Jr., and D. L. Hershman. 2009. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst. 101:984–992.

33. Siegel, R., E. Ward, O. Brawley, and A. Jemal. 2011. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236.

34. Hoffman, R. M., F. D. Gilliland, J. W. Eley, L. C. Harlan, R. A. Stephenson, J. L. Stanford, et al. 2001. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 93:388–395.

35. Daskivich, T. J., L. Kwan, A. Dash, and M. S. Litwin. 2015. Racial parity in tumor burden, treatment choice and survival outcomes in men with prostate cancer in the VA healthcare system. Prostate Cancer Prostatic Dis. 18:104–109.

36. Hamilton, R. J., W. J. Aronson, J. C. Presti Jr., M. K. Terris, C. J. Kane, C. L. Amling, et al. 2007. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer. 110:2202–2209.

37. Cooperberg, M. R. 2013. Re-examining racial disparities in prostate cancer outcomes. J Clin Oncol. 31:2979–2980.